Bulletin
Investor Alert

New York Markets Close in:

Market Snapshot Winners and Losers

Gilead Sciences Inc.

NAS: GILD

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Gilead Sciences Inc.

Countdown to close

 --Real time quotes

Mar 20, 2023, 3:47 p.m.

GILD
/zigman2/quotes/210293917/composite

$

79.44

Change

+2.13 +2.75%

Volume

Volume 2.67m

Real time quotes

/zigman2/quotes/210293917/composite

Previous close

$ 77.31

$ 79.44

Change

+2.13 +2.75%

Day low

Day high

$77.63

$79.44

Open

52 week low

52 week high

$57.17

$89.74

Open

Company Description

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology,...

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Valuation

P/E Current

21.94

P/E Ratio (with extraordinary items)

21.98

P/E Ratio (without extraordinary items)

23.59

Price to Sales Ratio

4.00

Price to Book Ratio

5.04

Price to Cash Flow Ratio

11.94

Enterprise Value to EBITDA

9.17

Enterprise Value to Sales

4.35

Efficiency

Total Asset Turnover

0.41

Liquidity

Current Ratio

1.29

Quick Ratio

1.15

Cash Ratio

0.61

Profitability

Gross Margin

79.11

Operating Margin

39.72

Pretax Margin

21.47

Net Margin

16.95

Return on Assets

7.00

Return on Equity

21.71

Return on Total Capital

22.70

Capital Structure

Total Debt to Total Assets

39.94

Officers and Executives

Name Age Officer Since Title
Mr. Daniel P. O'Day 56 2019 Chairman & Chief Executive Officer
Mr. Andrew D. Dickinson 51 2016 Chief Financial Officer
Dr. Merdad V. Parsey - 2019 Chief Medical Officer
Dr. Flavius Martin - 2021 Executive Vice President-Research
Ms. Johanna Mercier 50 2019 Chief Commercial Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
03/01/2023 Daniel P. O'Day
Chairman & CEO; Director 		4,842   Derivative/Non-derivative trans. at $79.59 per share. 385,374
03/01/2023 Merdad V. Parsey
Chief Medical Officer 		12,984   Disposition at $79.96 per share. 1,038,200
03/01/2023 Daniel P. O'Day
Chairman & CEO; Director 		11,362   Derivative/Non-derivative trans. at $0 per share. 0
02/15/2023 Andrew D. Dickinson
Chief Financial Officer 		376   Award at $56.38 per share. 21,198
02/15/2023 Merdad V. Parsey
Chief Medical Officer 		376   Award at $56.38 per share. 21,198
02/15/2023 Deborah H. Telman
EVP, Corporate Affairs & GC 		376   Award at $56.38 per share. 21,198
02/06/2023 Andrew D. Dickinson
Chief Financial Officer 		531   Derivative/Non-derivative trans. at $86.36 per share. 45,857
02/06/2023 Diane E. Wilfong
SVP, Controller & CAO 		565   Derivative/Non-derivative trans. at $86.36 per share. 48,793
02/06/2023 Andrew D. Dickinson
Chief Financial Officer 		1,817   Derivative/Non-derivative trans. at $0 per share. 0
02/06/2023 Diane E. Wilfong
SVP, Controller & CAO 		1,864   Derivative/Non-derivative trans. at $0 per share. 0
01/24/2023 Daniel P. O'Day
Chairman & CEO; Director 		59,078   Derivative/Non-derivative trans. at $84.02 per share. 4,963,733
01/24/2023 Andrew D. Dickinson
Chief Financial Officer 		15,327   Derivative/Non-derivative trans. at $84.02 per share. 1,287,774
01/24/2023 Johanna Mercier
Chief Commercial Officer 		15,325   Derivative/Non-derivative trans. at $84.02 per share. 1,287,606
01/24/2023 Merdad V. Parsey
Chief Medical Officer 		17,749   Derivative/Non-derivative trans. at $84.02 per share. 1,491,270
01/24/2023 Diane E. Wilfong
SVP, Controller & CAO 		1,244   Derivative/Non-derivative trans. at $84.02 per share. 104,520
01/24/2023 Daniel P. O'Day
Chairman & CEO; Director 		136,647   Award at $0 per share. 0
01/24/2023 Daniel P. O'Day
Chairman & CEO; Director 		78,370   Award at $0 per share. 0
01/24/2023 Andrew D. Dickinson
Chief Financial Officer 		38,270   Award at $0 per share. 0
01/24/2023 Andrew D. Dickinson
Chief Financial Officer 		27,932   Award at $0 per share. 0
01/24/2023 Johanna Mercier
Chief Commercial Officer 		38,270   Award at $0 per share. 0
01/24/2023 Johanna Mercier
Chief Commercial Officer 		29,124   Award at $0 per share. 0
01/24/2023 Merdad V. Parsey
Chief Medical Officer 		43,715   Award at $0 per share. 0
01/24/2023 Merdad V. Parsey
Chief Medical Officer 		29,644   Award at $0 per share. 0
01/24/2023 Diane E. Wilfong
SVP, Controller & CAO 		4,100   Award at $0 per share. 0
01/24/2023 Diane E. Wilfong
SVP, Controller & CAO 		1,784   Award at $0 per share. 0
12/30/2022 Merdad V. Parsey
Chief Medical Officer 		553   Disposition at $85.33 per share. 47,187
12/10/2022 Daniel P. O'Day
Chairman & CEO; Director 		1,542   Derivative/Non-derivative trans. at $87.97 per share. 135,649
12/10/2022 Andrew D. Dickinson
Chief Financial Officer 		480   Derivative/Non-derivative trans. at $87.97 per share. 42,225
12/10/2022 Johanna Mercier
Chief Commercial Officer 		463   Derivative/Non-derivative trans. at $87.97 per share. 40,730
12/10/2022 Merdad V. Parsey
Chief Medical Officer 		486   Derivative/Non-derivative trans. at $87.97 per share. 42,753
12/10/2022 Diane E. Wilfong
SVP, Controller & CAO 		149   Derivative/Non-derivative trans. at $87.97 per share. 13,107
12/10/2022 Daniel P. O'Day
Chairman & CEO; Director 		3,300   Derivative/Non-derivative trans. at $0 per share. 0
12/10/2022 Andrew D. Dickinson
Chief Financial Officer 		1,027   Derivative/Non-derivative trans. at $0 per share. 0
12/10/2022 Johanna Mercier
Chief Commercial Officer 		990   Derivative/Non-derivative trans. at $0 per share. 0
12/10/2022 Merdad V. Parsey
Chief Medical Officer 		1,039   Derivative/Non-derivative trans. at $0 per share. 0
12/10/2022 Diane E. Wilfong
SVP, Controller & CAO 		318   Derivative/Non-derivative trans. at $0 per share. 0
11/10/2022 Andrew D. Dickinson
Chief Financial Officer 		851   Derivative/Non-derivative trans. at $82.6 per share. 70,292
11/10/2022 Merdad V. Parsey
Chief Medical Officer 		2,268   Derivative/Non-derivative trans. at $82.6 per share. 187,336
11/10/2022 Andrew D. Dickinson
Chief Financial Officer 		1,912   Derivative/Non-derivative trans. at $0 per share. 0
11/10/2022 Merdad V. Parsey
Chief Medical Officer 		5,099   Derivative/Non-derivative trans. at $0 per share. 0
11/09/2022 Diane E. Wilfong
SVP, Controller & CAO 		6,416   Disposition at $83.5 per share. 535,736
11/09/2022 Diane E. Wilfong
SVP, Controller & CAO 		6,416   Derivative/Non-derivative trans. at $63.91 per share. 410,046
11/01/2022 Diane E. Wilfong
SVP, Controller & CAO 		16,255   Disposition at $79.25 per share. 1,288,208
11/01/2022 Diane E. Wilfong
SVP, Controller & CAO 		16,255   Derivative/Non-derivative trans. at $72.7 per share. 1,181,738
09/10/2022 Daniel P. O'Day
Chairman & CEO; Director 		1,528   Derivative/Non-derivative trans. at $65.28 per share. 99,747
09/10/2022 Andrew D. Dickinson
Chief Financial Officer 		476   Derivative/Non-derivative trans. at $65.28 per share. 31,073
09/10/2022 Johanna Mercier
Chief Commercial Officer 		458   Derivative/Non-derivative trans. at $65.28 per share. 29,898
09/10/2022 Merdad V. Parsey
Chief Medical Officer 		481   Derivative/Non-derivative trans. at $65.28 per share. 31,399
09/10/2022 Diane E. Wilfong
SVP, Controller & CAO 		148   Derivative/Non-derivative trans. at $65.28 per share. 9,661
09/10/2022 Daniel P. O'Day
Chairman & CEO; Director 		3,301   Derivative/Non-derivative trans. at $0 per share. 0
09/10/2022 Andrew D. Dickinson
Chief Financial Officer 		1,027   Derivative/Non-derivative trans. at $0 per share. 0
09/10/2022 Johanna Mercier
Chief Commercial Officer 		990   Derivative/Non-derivative trans. at $0 per share. 0
09/10/2022 Merdad V. Parsey
Chief Medical Officer 		1,039   Derivative/Non-derivative trans. at $0 per share. 0
09/10/2022 Diane E. Wilfong
SVP, Controller & CAO 		318   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/gild

MarketWatch News on GILD

  2. Nurix’s stock rallies on Gilead’s option

    9:00 a.m. Today

    - Jaimy Lee

  3. Moderna Inc. stock underperforms Friday when compared to competitors

    4:31 p.m. March 17, 2023

    - MarketWatch Automation

  4. Moderna Inc. stock rises Thursday, still underperforms market

    4:31 p.m. March 16, 2023

    - MarketWatch Automation

  5. Moderna Inc. stock underperforms Wednesday when compared to competitors

    4:31 p.m. March 15, 2023

    - MarketWatch Automation

  6. Moderna Inc. stock rises Tuesday, outperforms market

    4:31 p.m. March 14, 2023

    - MarketWatch Automation

  7. Moderna Inc. stock rises Monday, outperforms market

    4:31 p.m. March 13, 2023

    - MarketWatch Automation

  8. Moderna Inc. stock rises Friday, outperforms market

    4:31 p.m. March 10, 2023

    - MarketWatch Automation

  9. Moderna Inc. stock falls Thursday, underperforms market

    4:31 p.m. March 9, 2023

    - MarketWatch Automation

  10. Moderna Inc. stock rises Wednesday, outperforms market

    4:31 p.m. March 8, 2023

    - MarketWatch Automation

  11. Moderna Inc. stock falls Tuesday, underperforms market

    4:31 p.m. March 7, 2023

    - MarketWatch Automation

  12. Moderna Inc. stock outperforms market on strong trading day

    4:31 p.m. March 6, 2023

    - MarketWatch Automation

  13. Moderna Inc. stock outperforms competitors on strong trading day

    4:31 p.m. March 3, 2023

    - MarketWatch Automation

  14. Moderna Inc. stock outperforms market on strong trading day

    4:31 p.m. March 2, 2023

    - MarketWatch Automation

  15. Moderna Inc. stock underperforms Wednesday when compared to competitors

    4:31 p.m. March 1, 2023

    - MarketWatch Automation

  16. Moderna Inc. stock rises Tuesday, outperforms market

    4:31 p.m. Feb. 28, 2023

    - MarketWatch Automation

  17. Moderna's Covid Boom Is Ending. Why the Outlook Isn't All Grim.

    9:03 a.m. Feb. 28, 2023

    - Josh Nathan-Kazis

  18. Moderna Inc. stock falls Monday, underperforms market

    4:31 p.m. Feb. 27, 2023

    - MarketWatch Automation

  19. Moderna Inc. stock underperforms Friday when compared to competitors

    4:31 p.m. Feb. 24, 2023

    - MarketWatch Automation

  21. Loading more headlines...
/news/nonmarketwatch/company/us/gild

Other News on GILD

  2. First Drugs Facing Medicare Price Penalty Are Named

    12:50 p.m. March 15, 2023

    - Stephanie Armour

  3. Seagen’s Cancer Therapy Is Making It a Takeover Target

    12:29 p.m. March 6, 2023

    - Jared S. Hopkins

  4. Guild Esports launches Guild Studios

    5:00 a.m. March 2, 2023

    - TheNewswire.ca

  5. 10-K: GILEAD SCIENCES, INC.

    4:30 p.m. Feb. 22, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  7. AQR CAPITAL MANAGEMENT LLC Buys 3, Sells 2 in 4th Quarter

    10:00 p.m. Feb. 17, 2023

    - GuruFocus.com

  8. VALUEWORKS LLC Buys 1, Sells 4 in 4th Quarter

    8:00 p.m. Feb. 17, 2023

    - GuruFocus.com

  9. Top 5 4th Quarter Trades of HealthInvest Partners AB

    6:00 p.m. Feb. 17, 2023

    - GuruFocus.com

  10. Top 5 4th Quarter Trades of Nan Shan Life Insurance Co., Ltd.

    2:00 p.m. Feb. 16, 2023

    - GuruFocus.com

  11. Top 5 4th Quarter Trades of Avalon Investment & Advisory

    2:00 a.m. Feb. 15, 2023

    - GuruFocus.com

  12. Caxton Associates Buys 4, Sells 1 in 4th Quarter

    6:00 p.m. Feb. 14, 2023

    - GuruFocus.com

  13. John Rogers Buys 3, Sells 2 in 4th Quarter

    10:00 a.m. Feb. 14, 2023

    - GuruFocus.com

  14. This Top Dividend Stock Just Hiked Its Payouts Again

    11:59 a.m. Feb. 13, 2023

    - Baystreet.ca

  15. GLOBEFLEX CAPITAL L P Buys 4, Sells 1 in 4th Quarter

    4:00 p.m. Feb. 12, 2023

    - GuruFocus.com

  16. Top 5 4th Quarter Trades of KLCM Advisors, Inc.

    4:00 p.m. Feb. 12, 2023

    - GuruFocus.com

  17. Goodman Financial CORP Buys 2, Sells 3 in 4th Quarter

    2:00 p.m. Feb. 9, 2023

    - GuruFocus.com

  18. Top 5 4th Quarter Trades of SECTOR GAMMA AS

    2:00 p.m. Feb. 8, 2023

    - GuruFocus.com

  19. Top 5 4th Quarter Trades of VAN ECK ASSOCIATES CORP

    2:00 p.m. Feb. 8, 2023

    - GuruFocus.com

  21. Loading more headlines...

At a Glance

Gilead Sciences, Inc.

333 Lakeside Drive

Foster City, California 94404

Phone

1 6505743000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2023

View SEC Filings

Revenue

$27.09B

Net Income

$4.59B

Employees

17,000

Annual Report for GILD

/news/pressrelease/company/us/gild

Press Releases on GILD

  5. Gilead Sciences $GILD Investment Analysis and Advice

    4:17 a.m. March 14, 2023

    - Stock Traders Daily

  8. Gilead Sciences $GILD Technical Pivots with Risk Controls

    1:11 p.m. March 4, 2023

    - Stock Traders Daily

  10. Guild Esports launches Guild Studios

    6:00 a.m. March 2, 2023

    - TheNewswire.ca

  13. Gilead Sciences (GILD) Trading Report

    9:52 p.m. Feb. 22, 2023

    - Stock Traders Daily

  15. Kite Completes Acquisition of Tmunity

    10:00 a.m. Feb. 22, 2023

    - BusinessWire - BZX

  21. Loading more headlines...
Link to MarketWatch's Slice.